Xu Haoxin, Zhou Jingyu, Yang Qingluan, Yang Yixuan, Zhou Feiran, Qian Mengqing, Lin Xing, Zhang Wenhong, Shao Lingyun, Ruan Qiaoling
Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Int J Infect Dis. 2025 Aug;157:107915. doi: 10.1016/j.ijid.2025.107915. Epub 2025 May 3.
Despite the higher specificity and reliability of detecting latent tuberculosis (TB) infection, Mycobacterium tuberculosis-specific interferon (IFN)-γ release assays do not perform satisfactorily in predicting the risk of active TB (ATB) development. It is crucial to identify new biomarkers with high predictive accuracy to identify individuals bearing a high risk of progression.
This was a sub-study of an open-label, randomized clinical trial for prevention of TB in silicosis patients. Twenty-six participants were diagnosed with ATB within 37-month' follow-up. They were defined as TB progressors and matched in a 1:2 ratio with 52 TB nonprogressors.
We analyzed expression of 45 cytokines in QuantiFERON supernatants from TB progressors and nonprogressors, and granulocyte-macrophage colony-stimulating factor, vascular endothelial growth factor, interleukin (IL)-3, IFN-γ-induced protein 10, IL-10, and IL-9 outperformed IFN-γ as predictive markers.
These findings highlight the potential of new biomarkers in identifying individuals with high risk of TB to undergo early intervention.
ClinicalTrials.gov number: NCT02430259.
尽管检测潜伏性结核（TB）感染具有更高的特异性和可靠性，但结核分枝杆菌特异性干扰素（IFN）-γ释放试验在预测活动性结核（ATB）发生风险方面表现并不令人满意。识别具有高预测准确性的新生物标志物以确定进展风险高的个体至关重要。
这是一项针对矽肺患者预防结核的开放标签随机临床试验的子研究。26名参与者在37个月的随访中被诊断为ATB。他们被定义为结核进展者，并以1:2的比例与52名结核非进展者匹配。
我们分析了结核进展者和非进展者的QuantiFERON上清液中45种细胞因子的表达，粒细胞-巨噬细胞集落刺激因子、血管内皮生长因子、白细胞介素（IL）-3、IFN-γ诱导蛋白10、IL-10和IL-9作为预测标志物优于IFN-γ。
这些发现凸显了新生物标志物在识别结核高风险个体以进行早期干预方面的潜力。
ClinicalTrials.gov编号：NCT02430259。
